# Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

> **NCT05986864** · PHASE1,PHASE2 · RECRUITING · sponsor: **Skyline Therapeutics (US) Inc.** · enrollment: 68 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **GENETIC:** SKG0106

## Key facts

- **NCT ID:** NCT05986864
- **Lead sponsor:** Skyline Therapeutics (US) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-23
- **Primary completion:** 2026-01
- **Final completion:** 2026-01-30
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986864, "Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05986864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*